Elevance Health
NYSE: ELV
Stock price
441.4 USD
(+1.86%) 5 years
Financial Performance
5Y price score: 2
The price score is a basic measure of the stock's performance against the S&P 500 Index over a five-year period.
A score of 100 indicates that the stock did as well as the S&P 500 Index.
A score below 100 means the stock underperformed the index, while a score above 100 means it outperformed the S&P 500.
10Y return: 293.2%
%
ㅤ
By default your notes are visible only to you.
274.8
52-week range
450.6
Your model inputs
Your fair value & Margin of safety
To calculate fair value based on cost of capital and terminal growth assumptions above, please select free cash flow forecast.
Forecast:
Valuation
Free Cash Flow Yield
6.7 %
Dividend Yield TTM
1.6 %
Market cap $
$ 95,726
Price / Earnings TTM
18.8
Price / Book TTM
2.1
PEG TTM
(8.6)
Earnings growth and return
LTM
5YR
10YR
Total return (price & dividends)
29.9 %
8.5 %
293.2 %
Free cash flow per share growth
33.9 %
(62.4) %
11.2 %
Earnings per share growth
17.9 %
39.7 %
167.8 %
Founded: 2,014
Employees: 104,200
Business Summary:
Q&A
Contribute
By providing well-researched and detailed answer you increase your chance of becoming Top Contributor. TopFunds is free for all top contributors. Learn more
Latest Earnings Call Takeaways
2026 Q3 (Oct 21, 2026)
1) Strong Q3 Performance and Guidance Update - Elevance Health reported adjusted diluted EPS of $6.99, exceeding expectations. - The company raised its 2026 adjusted diluted EPS guidance to at least $29, with a new earnings baseline of at least $26.75. - The outlook for 2027 includes at least 12% adjusted EPS growth, driven by margin improvements in health benefits and expanded adoption of Carelon's solutions.
2) Segment Performance Highlights - Medicaid: Performance exceeded expectations due to recent rate actions, with margins slightly ahead of prior guidance. The company anticipates further margin improvement in 2027. - Medicare Advantage: Focused on sustainable value delivery, with a full-year operating margin expected to be at least 2%. Approximately half of members will be in plans rated 4 stars or higher. - Individual ACA: Enrollment is expected to end the year at least 1.2 million members, with improved margins due to favorable claims experience and retention.
3) Operational Initiatives and Cost Management - Elevance is enhancing clinical oversight and care management in Medicaid, which is expected to support margin improvements. - Carelon's risk-based oncology solution has reduced avoidable inpatient admissions by 15%. - The Elevate medical cost management platform has identified over $300 million in anticipated savings this year.
4) Challenges and Market Dynamics - Medicaid margins are still under pressure from elevated cost trends, though they are stabilizing. - The company is navigating the complexities of the independent dispute resolution (IDR) process, which has implications for cost management and pricing strategies. - The transition to work requirements in Medicaid is being monitored closely, with potential impacts on membership and acuity.
5) Outlook and Future Strategies - Elevance is optimistic about entering 2027 with a stronger earnings baseline and visibility. - The company is focused on disciplined pricing strategies across its segments, particularly in Commercial and Medicare Advantage. - There is a commitment to integrating Carelon's capabilities to enhance service delivery and improve overall health outcomes.
Bottom line: Elevance Health's strong Q3 results and revised guidance reflect solid operational execution and strategic initiatives, positioning the company for sustainable growth in 2027 and beyond, despite ongoing challenges in the Medicaid segment.
Annual Reports, Presentations And IR Contacts
Go to the websiteElevance Health — Financial Overview, Stock Price, Market Cap
Elevance Health is a company. Founded in 2014. As of October 23, 2026, the company's market capitalization is $95726104606 with a current stock price of $441.40.